-transparent.png){kind=logo}
Since calcium channel antagonists are a diverse class of drugs frequently administered in combination with other agents, the potential for clinically significant pharmacokinetic drug interactions exists. These interactions occur most frequently via altered hepatic blood flow and impaired hepatic enzyme activity. Part I of the article, which appeared in the previous issue of the Journal, dealt with interactions between calcium antagonists and marker compounds, theophylline, midazolam, lithium, doxorubicin, oral hypoglycaemics and cardiac drugs. Part II examines interactions with cyclosporin, anaesthetics, carbamazepine and cardiovascular agents.
Related Publications
K D Schlanz, and
S A Myre, and
M B Bottorff
February 1990,
Clinical pharmacokinetics,
K D Schlanz, and
S A Myre, and
M B Bottorff
November 1990,
Clinical pharmacokinetics,
K D Schlanz, and
S A Myre, and
M B Bottorff
July 1988,
Cardiovascular drugs and therapy,
K D Schlanz, and
S A Myre, and
M B Bottorff
January 1988,
Cardiovascular drugs and therapy,
K D Schlanz, and
S A Myre, and
M B Bottorff
July 1988,
Cardiovascular drugs and therapy,
K D Schlanz, and
S A Myre, and
M B Bottorff
January 1994,
Postgraduate medicine,
K D Schlanz, and
S A Myre, and
M B Bottorff
August 1993,
The Practitioner,
K D Schlanz, and
S A Myre, and
M B Bottorff
May 1985,
The Journal of general physiology,
K D Schlanz, and
S A Myre, and
M B Bottorff
February 1983,
Drugs,
K D Schlanz, and
S A Myre, and
M B Bottorff
June 1998,
Pharmacology, biochemistry, and behavior,
